Form 4: Director Saira Ramasastry Executes Mirum Stock Sale

Director Saira Ramasastry exercised restricted stock units and sold 3,977 shares of Mirum Pharmaceuticals common stock.

Summary

• Director Saira Ramasastry acquired 3,977 shares of common stock through the vesting of restricted stock units on May 29, 2026.
• The reporting person subsequently sold the entire 3,977 shares on June 1, 2026, at a price of $100.00 per share.
• The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on September 18, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was executed under a pre-planned 10b5-1 arrangement, which is a standard mechanism for insider liquidity.

Positives

• The transaction was conducted under a pre-planned Rule 10b5-1 trading plan, which typically indicates the sale was not based on non-public information.

Negatives

• The director liquidated their entire recent acquisition of 3,977 shares immediately following the vesting event.

Risks

• Insider selling can sometimes be perceived by the market as a lack of long-term confidence in the stock price, though this was part of a pre-planned arrangement.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice for corporate directors and executives to manage personal liquidity and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to avoid potential conflicts of interest or allegations of insider trading.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a standard equity compensation liquidation.

Key Dates

Keywords

MIRM, Mirum Pharmaceuticals, Insider Trading, Form 4, Equity Compensation, Rule 10b5-1